Get weekly updates on this stock
AM The YouTuber recommends Amgen for its 2.9% dividend and strong diversification across sectors. As a large drugmaker, Amgen has a solid pipeline and…
The YouTuber suggests AMGEN as a counter-cyclical stock in the healthcare sector, which historically performs well during crises. He notes its good historical performance and current valuation at 14 times earnings, making it an attractive option.
The YouTuber suggests AMGEN as a counter-cyclical stock in the healthcare sector, which historically performs well during crises. He notes its good historical performance and current valuation at 14 times earnings, making it an attractive option.
“Tenéis AMGEN, empresa del sector de salud con un desempeño muy bueno histórico 14 veces.”
The analyst recommends Amgen as a safety stock within the healthcare sector. He identifies healthcare as a value sector that can protect money during a market correction, implying Amgen is attractively valued.
The analyst recommends Amgen as a safety stock within the healthcare sector. He identifies healthcare as a value sector that can protect money during a market correction, implying Amgen is attractively valued.
“You've also got Amgen there's Humanana ticker HUM down 14% over the last year.”
The YouTuber identifies Amgen as a well-positioned pharmaceutical company within the healthcare sector, which is expected to see significant earnings growth in 2025. He suggests it as a good investment for safety and growth within the broader healthcare theme.
“within this group amen ticker amgn and Eli Lily ticker LL are the best positioned with in those Pharmaceuticals”
The YouTuber recommends Amgen for its 2.9% dividend and strong diversification across sectors. As a large drugmaker, Amgen has a solid pipeline and financial power for acquisitions. Product sales jumped 20% last quarter due to volume growth. While R&D spending led to a 45% earnings drop, this spending should translate to future earnings, and the payout ratio remains safe.
“As a$1 170 billion drugmaker amen always has a solid Pipeline and the financial power to acquire it Product sales jumped 20% in the last quarter”
Amgen is entering the weight loss market with a monthly regimen drug, AMGN133, which showed promising early-stage trial data with 15% weight loss in 85 days. The YouTuber highlights its unique mechanism of action, blocking certain gut hormones, which could lead to more durable weight loss. Despite being years behind competitors, its current valuation at 15.7 times PE, a 35% discount to its long-term average, makes it attractive.
“shares trade for 15.7 times PE that's a 35 discount to its long-term average so like Pfizer here we do see an attractive valuation on this one.”
Amgen is recommended for its solid 3.6% dividend and robust drug pipeline, with over 24 indications in Phase 3 trials. The pending acquisition of Horizon Therapeutics is expected to help the company avoid the 'patent cliff' and continue its 11% annual dividend growth, with shares currently trading at a discount to fair value.
“Amgen always has a strong Pipeline with over 24 indications now in Phase 3 trials that combined with the pending acquisition of horizon Therapeutics for its Immunology business should help the company avoid the patent cliff in revenues.”
The YouTuber highlights Amgen Inc. as a dependable dividend stock with a strong pipeline and consistent performance. The company reported stellar Q1 results, generating significant free cash flow, raising its dividend, and reaffirming its 2022 earnings guidance, which is crucial in the current market. Its strong drug launches and extensive clinical trial pipeline ensure continued sales growth. It also showed resilience during the last market crash.
“One of the most dependable dividend stocks on the list amgen inc ticker amgn pays a 3.36 dividend and has returned another 7 annually on the price”
A named stock, a clear buy or sell stance, and real reasoning. Passing mentions and hype are filtered out.
Each channel counts once per stock, so a single loud voice can't skew the ranking.
We weigh how many creators agree, how convinced they are, and how recent each call is.
2 finance YouTubers analysed Amgen with qualified reasoning — consensus: Buy, average analysis quality 78/100. This is not financial advice; review the individual analyses and sources above.
Among the channels covering Amgen, 2 are buying and 0 are selling or avoiding — overall Buy.
The price targets mentioned for Amgen range 246. Targets are the YouTubers' own; not a guarantee.
Only qualified analyses count: a clear buy/sell stance on Amgen with real reasoning (valuation, fundamentals, a catalyst or a chart setup). Passing mentions are excluded.